<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38105651</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2125</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>British journal of clinical pharmacology</Title><ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial.</ArticleTitle><Pagination><StartPage>1081</StartPage><EndPage>1093</EndPage><MedlinePgn>1081-1093</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bcp.15988</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To conduct a single-arm open-label feasibility trial of the safety and tolerability of a full-spectrum cannabidiol (CBD)-dominant cannabis-based medicinal product for treating the symptoms of long COVID.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The treatment phase ran for a total of 21&#x2009;weeks, followed by ~3&#xa0;weeks without the study drug. Participants received up to 3&#xa0;mL of MediCabilis 5% CBD Oil (50&#x2009;mg CBD/mL, &lt;2&#xa0;mg &#x3b4;-9-tetrahydrocannabinol/mL) per day orally. Monthly patient-reported outcome measures of common symptoms and daily self-report of symptoms were collected via a smartphone app. Key measures of heart rate, activity, sleep and oxygen saturation were assessed using wearable technology.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twelve (1 male, 11 female) individuals diagnosed with long COVID were recruited into the trial. All participants adhered to the treatment protocol for the duration of the study and there were no serious adverse events. Response rates for the research assessments were high with over 90% completion of patient-reported outcome measures and daily self-report.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The study drug was safe and well-tolerated, demonstrating feasibility of CBD-dominant cannabis-based medicinal products in individuals diagnosed with long COVID. However, there were limitations in research design related to recruitment strategy demonstrating a lack of feasibility in the approach implemented in this study. Future work with larger samples and incorporating a control group are required to test the efficacy of this treatment.</AbstractText><CopyrightInformation>&#xa9; 2023 British Pharmacological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thurgur</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-7714-3446</Identifier><AffiliationInfo><Affiliation>Drug Science, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynskey</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Drug Science, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlag</LastName><ForeName>Anne Katrin</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Drug Science, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Croser</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Nutt</LastName><ForeName>David John</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-1286-1401</Identifier><AffiliationInfo><Affiliation>Drug Science, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iveson</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Stroke and Neurorehabilitation, Nuffield Health, York, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Clin Pharmacol</MedlineTA><NlmUniqueID>7503323</NlmUniqueID><ISSNLinking>0306-5251</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>19GBJ60SN5</RegistryNumber><NameOfSubstance UI="D002185">Cannabidiol</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006213">Hallucinogens</NameOfSubstance></Chemical><Chemical><RegistryNumber>7J8897W37S</RegistryNumber><NameOfSubstance UI="D013759">Dronabinol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002185" MajorTopicYN="Y">Cannabidiol</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002188" MajorTopicYN="Y">Cannabis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006213" MajorTopicYN="Y">Hallucinogens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013759" MajorTopicYN="N">Dronabinol</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cannabidiol</Keyword><Keyword MajorTopicYN="N">cannabis&#x2010;based medicinal products</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">medical cannabis</Keyword><Keyword MajorTopicYN="N">post&#x2010;coronavirus disease&#x2010;19 syndrome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>18</Day><Hour>3</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38105651</ArticleId><ArticleId IdType="doi">10.1111/bcp.15988</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>World Health Organization. A clinical case definition of post COVID&#x2010;19 condition by a Delphi consensus. Published online 6 October 2021. Accessed June 2, 2023. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1</Citation></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi:10.1016/j.eclinm.2021.101019</Citation></Reference><Reference><Citation>Lopez&#x2010;Leon S, Wegman&#x2010;Ostrosky T, Perelman C, et al. More than 50 long&#x2010;term effects of COVID&#x2010;19: a systematic review and meta&#x2010;analysis. Sci Rep. 2021;11(1):16144. doi:10.1038/s41598&#x2010;021&#x2010;95565&#x2010;8</Citation></Reference><Reference><Citation>O'Mahoney LL, Routen A, Gillies C, et al. The prevalence and long&#x2010;term health effects of long Covid among hospitalised and non&#x2010;hospitalised populations: a systematic review and meta&#x2010;analysis. EClinicalMedicine. 2023;55:101762. doi:10.1016/j.eclinm.2022.101762</Citation></Reference><Reference><Citation>Walker S, Goodfellow H, Pookarnjanamorakot P, et al. Impact of fatigue as the primary determinant of functional limitations among patients with post&#x2010;COVID&#x2010;19 syndrome: a cross&#x2010;sectional observational study. BMJ Open. 2023;13(6):e069217. doi:10.1136/bmjopen&#x2010;2022&#x2010;069217</Citation></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;de&#x2010;Las&#x2010;Pe&#xf1;as C, Palacios&#x2010;Ce&#xf1;a D, G&#xf3;mez&#x2010;Mayordomo V, et al. Prevalence of post&#x2010;COVID&#x2010;19 symptoms in hospitalized and non&#x2010;hospitalized COVID&#x2010;19 survivors: a systematic review and meta&#x2010;analysis. Eur J Intern Med. 2021;92:55&#x2010;70. doi:10.1016/j.ejim.2021.06.009</Citation></Reference><Reference><Citation>Pavli A, Theodoridou M, Maltezou HC. Post&#x2010;COVID syndrome: incidence, clinical Spectrum, and challenges for primary healthcare professionals. Arch Med Res. 2021;52(6):575&#x2010;581. doi:10.1016/j.arcmed.2021.03.010</Citation></Reference><Reference><Citation>Alkodaymi MS, Omrani OA, Fawzy NA, et al. Prevalence of post&#x2010;acute COVID&#x2010;19 syndrome symptoms at different follow&#x2010;up periods: a systematic review and meta&#x2010;analysis. Clin Microbiol Infect. 2022;28(5):657&#x2010;666. doi:10.1016/j.cmi.2022.01.014</Citation></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post&#x2010;coronavirus disease 2019 (COVID&#x2010;19) condition or long COVID: a meta&#x2010;analysis and systematic review. J Infect Dis. 2022;226(9):1593&#x2010;1607. doi:10.1093/infdis/jiac136</Citation></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, et al. Post&#x2010;COVID syndrome in non&#x2010;hospitalised patients with COVID&#x2010;19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021;6:100122. doi:10.1016/j.lanepe.2021.100122</Citation></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein&#x2010;Barr virus reactivation. Pathogens. 2021;10(6):763. doi:10.3390/pathogens10060763</Citation></Reference><Reference><Citation>Thurgur H, Schlag AK, Iveson E, Hosseini A, Lynskey M, Nutt DJ. Cannabis&#x2010;based medicinal products (CBMPs) for the treatment of long COVID symptoms: current and potential applications. Exp Ther Med. 2023;4(4):487&#x2010;503. doi:10.37349/emed.2023.00158</Citation></Reference><Reference><Citation>Ueberall MA, Essner U, Mueller&#x2010;Schwefe GH. Effectiveness and tolerability of THC:CBD oromucosal spray as add&#x2010;on measure in patients with severe chronic pain: analysis of 12&#x2010;week open&#x2010;label real&#x2010;world data provided by the German pain e&#x2010;registry. J Pain Res. 2019;12:1577&#x2010;1604. doi:10.2147/JPR.S192174</Citation></Reference><Reference><Citation>Gulbransen G, Xu W, Arroll B. Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP Open. 2020;4(1):bjgpopen20X101010. doi:10.3399/bjgpopen20X101010</Citation></Reference><Reference><Citation>Wright M, Di Ciano P, Brands B. Use of Cannabidiol for the treatment of anxiety: a short synthesis of pre&#x2010;clinical and clinical evidence. Cannabis Cannabinoid Res. 2020;5(3):191&#x2010;196. doi:10.1089/can.2019.0052</Citation></Reference><Reference><Citation>Moreno&#x2010;Sanz G, Madiedo A, Lynskey M, Brown MRD. &#x2018;Flower power&#x2019;: controlled inhalation of THC&#x2010;predominant cannabis Flos improves health&#x2010;related quality of life and symptoms of chronic pain and anxiety in eligible UK patients. Biomedicine. 2022;10(10):2576. doi:10.3390/biomedicines10102576</Citation></Reference><Reference><Citation>Nutt DJ, Phillips LD, Barnes MP, et al. A multicriteria decision analysis comparing pharmacotherapy for chronic neuropathic pain, including cannabinoids and cannabis&#x2010;based medical products. Cannabis Cannabinoid Res. 2022;7(4):482&#x2010;500. doi:10.1089/can.2020.0129</Citation></Reference><Reference><Citation>Lynskey MT, Schlag AK, Athanasiou&#x2010;Fragkouli A, Badcock D, Nutt DJ. Characteristics of and 3&#x2010;month health outcomes for people seeking treatment with prescribed cannabis: real&#x2010;world evidence from project Twenty21. Drug Sci Policy Law. 2023;9:20503245231167373. doi:10.1177/20503245231167373</Citation></Reference><Reference><Citation>Olsson F, Erridge S, Tait J, et al. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom medical cannabis registry. Expert Rev Clin Pharmacol. 2023;16(3):257&#x2010;266. doi:10.1080/17512433.2023.2183841</Citation></Reference><Reference><Citation>Stith SS, Vigil JM, Brockelman F, Keeling K, Hall B. Patient&#x2010;reported symptom relief following medical cannabis consumption. Front Pharmacol. 2018;9:916. doi:10.3389/fphar.2018.00916</Citation></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long&#x2010;haul COVID. Nat Immunol. 2022;23(2):194&#x2010;202. doi:10.1038/s41590&#x2010;021&#x2010;01104&#x2010;y</Citation></Reference><Reference><Citation>Atalay S, Jarocka&#x2010;Karpowicz I, Skrzydlewska E. Antioxidative and anti&#x2010;inflammatory properties of Cannabidiol. Antioxid Basel. 2019;9(1):21. doi:10.3390/antiox9010021</Citation></Reference><Reference><Citation>Lowin T, Tingting R, Zurmahr J, Classen T, Schneider M, Pongratz G. Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts. Cell Death Dis. 2020;11(8):714. doi:10.1038/s41419&#x2010;020&#x2010;02892&#x2010;1</Citation></Reference><Reference><Citation>Anil SM, Shalev N, Vinayaka AC, et al. Cannabis compounds exhibit anti&#x2010;inflammatory activity in vitro in COVID&#x2010;19&#x2010;related inflammation in lung epithelial cells and pro&#x2010;inflammatory activity in macrophages. Sci Rep. 2021;11(1):1462. doi:10.1038/s41598&#x2010;021&#x2010;81049&#x2010;2</Citation></Reference><Reference><Citation>Robaina Cabrera CL, Keir&#x2010;Rudman S, Horniman N, Clarkson N, Page C. The anti&#x2010;inflammatory effects of cannabidiol and cannabigerol alone, and in combination. Pulm Pharmacol Ther. 2021;69:102047. doi:10.1016/j.pupt.2021.102047</Citation></Reference><Reference><Citation>Sarkar I, Sen G, Bhattacharya M, Bhattacharyya S, Sen A. Inquest reveals the efficacy of cannabis in the treatment of post&#x2010;Covid&#x2010;19 related neurodegeneration. J Biomol Struct Dyn. 2022;40(17):8030&#x2010;8039. doi:10.1080/07391102.2021.1905556</Citation></Reference><Reference><Citation>Chadda KR, Blakey EE, Huang CL, Jeevaratnam K. Long COVID&#x2010;19 and postural orthostatic tachycardia syndrome&#x2010; is Dysautonomia to be blamed? Front Cardiovasc Med. 2022;9:860198. doi:10.3389/fcvm.2022.860198</Citation></Reference><Reference><Citation>Eldokla AM, Mohamed&#x2010;Hussein AA, Fouad AM, et al. Prevalence and patterns of symptoms of dysautonomia in patients with long&#x2010;COVID syndrome: a cross&#x2010;sectional study. Ann Clin Transl Neurol. 2022;9(6):778&#x2010;785. doi:10.1002/acn3.51557</Citation></Reference><Reference><Citation>Larsen NW, Stiles LE, Shaik R, et al. Characterization of autonomic symptom burden in long COVID: a global survey of 2,314 adults. Front Neurol. 2022;13:1012668. doi:10.3389/fneur.2022.1012668</Citation></Reference><Reference><Citation>Barizien N, Le Guen M, Russel S, Touche P, Huang F, Vall&#xe9;e A. Clinical characterization of dysautonomia in long COVID&#x2010;19 patients. Sci Rep. 2021;11(1):14042. doi:10.1038/s41598&#x2010;021&#x2010;93546&#x2010;5</Citation></Reference><Reference><Citation>Hosseini A, McLachlan AJ, Lickliter JD. A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single&#x2010;dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. Br J Clin Pharmacol. 2021;87(4):2070&#x2010;2077. doi:10.1111/bcp.14617</Citation></Reference><Reference><Citation>Sivan M, Halpin S, Gee J, et al. The self&#x2010;report version and digital format of the COVID&#x2010;19 Yorkshire rehabilitation scale (C19&#x2010;YRS) for long Covid or post&#x2010;COVID syndrome assessment and monitoring. Adv Clin Neurosci Rehabil. 2021;20(3). doi:10.47795/QROO4168</Citation></Reference><Reference><Citation>Krupp LB, LaRocca NG, Muir&#x2010;Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121&#x2010;1123. doi:10.1001/archneur.1989.00520460115022</Citation></Reference><Reference><Citation>Cleeland C. Measurement of pain by subjective report. In: Chapman CR, Loeser JD, eds. Issues in pain measurement. Vol.12(Advances in Pain Research and Therapy). N Y Raven Press; 1989:391&#x2010;403.</Citation></Reference><Reference><Citation>Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore. 1994;23(2):129&#x2010;138.</Citation></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JBW. The PHQ&#x2010;9. J Gen Intern Med. 2001;16(9):606&#x2010;613. doi:10.1046/j.1525&#x2010;1497.2001.016009606.x</Citation></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JBW, L&#xf6;we B. A brief measure for assessing generalized anxiety disorder: the GAD&#x2010;7. Arch Intern Med. 2006;166(10):1092&#x2010;1097. doi:10.1001/archinte.166.10.1092</Citation></Reference><Reference><Citation>Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193&#x2010;213. doi:10.1016/0165&#x2010;1781(89)90047&#x2010;4</Citation></Reference><Reference><Citation>Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health&#x2010;related quality of life: an EQ&#x2010;5D&#x2010;5L value set for England. Health Econ. 2018;27(1):7&#x2010;22. doi:10.1002/hec.3564</Citation></Reference><Reference><Citation>Alexander SPH, Christopoulos A, Davenport AP, et al. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein&#x2010;coupled receptors. Br J Pharmacol. 2021;178(S1):S27&#x2010;S156. doi:10.1111/bph.15538</Citation></Reference><Reference><Citation>Janssen MF, Bonsel GJ, Luo N. Is EQ&#x2010;5D&#x2010;5L better than EQ&#x2010;5D&#x2010;3L? A head&#x2010;to&#x2010;head comparison of descriptive systems and value sets from seven countries. Pharmacoeconomics. 2018;36(6):675&#x2010;697. doi:10.1007/s40273&#x2010;018&#x2010;0623&#x2010;8</Citation></Reference><Reference><Citation>Dahlgren MK, Lambros AM, Smith RT, Sagar KA, El&#x2010;Abboud C, Gruber SA. Clinical and cognitive improvement following full&#x2010;spectrum, high&#x2010;cannabidiol treatment for anxiety: open&#x2010;label data from a two&#x2010;stage, phase 2 clinical trial. Commun Med Lond. 2022;2(1):139. doi:10.1038/s43856&#x2010;022&#x2010;00202&#x2010;8</Citation></Reference><Reference><Citation>Bhaskar A, Bell A, Boivin M, et al. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. J Cannabis Res. 2021;3(1):22. doi:10.1186/s42238&#x2010;021&#x2010;00073&#x2010;1</Citation></Reference><Reference><Citation>Shaver J. The state of telehealth before and after the COVID&#x2010;19 pandemic. Prim Care. 2022;49(4):517&#x2010;530. doi:10.1016/j.pop.2022.04.002</Citation></Reference><Reference><Citation>OECD. The COVID&#x2010;19 pandemic and the future of telemedicine. Published Online 2023. https://www.oecd-ilibrary.org/content/publication/ac8b0a27-en</Citation></Reference><Reference><Citation>Inan OT, Tenaerts P, Prindiville SA, et al. Digitizing clinical trials. Npj Digit Med. 2020;3(1):101. doi:10.1038/s41746&#x2010;020&#x2010;0302&#x2010;y</Citation></Reference><Reference><Citation>Cooper ZD, Craft RM. Sex&#x2010;dependent effects of cannabis and cannabinoids: a translational perspective. Neuropsychopharmacol off Publ Am Coll Neuropsychopharmacol. 2018;43(1):34&#x2010;51. doi:10.1038/npp.2017.140</Citation></Reference><Reference><Citation>Liu J, Lu YF, Corton JC, Klaassen CD. Expression of cytochrome P450 isozyme transcripts and activities in human livers. Xenobiotica. 2021;51(3):279&#x2010;286. doi:10.1080/00498254.2020.1867929</Citation></Reference><Reference><Citation>Sholler DJ, Strickland JC, Spindle TR, Weerts EM, Vandrey R. Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. Addict Biol. 2021;26(4):e12968. doi:10.1111/adb.12968</Citation></Reference><Reference><Citation>Reese JT, Blau H, Casiraghi E, et al. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. EBioMedicine. 2023;87:104413. doi:10.1016/j.ebiom.2022.104413</Citation></Reference><Reference><Citation>Munblit D, Nicholson T, Akrami A, et al. A core outcome set for post&#x2010;COVID&#x2010;19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respir Med. 2022;10(7):715&#x2010;724. doi:10.1016/S2213&#x2010;2600(22)00169&#x2010;2</Citation></Reference><Reference><Citation>Schlag AK, Zafar RR, Lynskey MT, Athanasiou&#x2010;Fragkouli A, Phillips LD, Nutt DJ. The value of real world evidence: the case of medical cannabis. Front Psych. 2022;13:1027159. doi:10.3389/fpsyt.2022.1027159</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>